201 related articles for article (PubMed ID: 37200859)
41. Fas-FasL interaction in cytotoxic T cell-mediated vitiligo: The role of lesional expression of tumor necrosis factor-α and interferon-γ in Fas-mediated melanocyte apoptosis.
Jimbo H; Nagai H; Fujiwara S; Shimoura N; Nishigori C
Exp Dermatol; 2020 Jan; 29(1):61-70. PubMed ID: 31675451
[TBL] [Abstract][Full Text] [Related]
42. Inhibiting Lysine Demethylase 1A Improves L1CAM-Specific CAR T Cell Therapy by Unleashing Antigen-Independent Killing via the FAS-FASL Axis.
Sulejmani O; Grunewald L; Andersch L; Schwiebert S; Klaus A; Winkler A; Astrahantseff K; Eggert A; Henssen AG; Schulte JH; Anders K; Künkele A
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771652
[TBL] [Abstract][Full Text] [Related]
43. IRF-1 inhibits NF-κB activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition.
Armstrong MJ; Stang MT; Liu Y; Yan J; Pizzoferrato E; Yim JH
Cancer Biol Ther; 2015; 16(7):1029-41. PubMed ID: 26011589
[TBL] [Abstract][Full Text] [Related]
44. CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.
Andersch L; Radke J; Klaus A; Schwiebert S; Winkler A; Schumann E; Grunewald L; Zirngibl F; Flemmig C; Jensen MC; Rossig C; Joussen A; Henssen A; Eggert A; Schulte JH; Künkele A
BMC Cancer; 2019 Sep; 19(1):895. PubMed ID: 31500597
[TBL] [Abstract][Full Text] [Related]
45. Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers.
Ba H; Dai Z; Zhang Z; Zhang P; Yin B; Wang J; Li Z; Zhou X
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36720496
[TBL] [Abstract][Full Text] [Related]
46. RIP1 has a role in CD40-mediated apoptosis in human follicular lymphoma cells.
Adem J; Eray M; Eeva J; Nuutinen U; Pelkonen J
Immunobiology; 2017 Nov; 222(11):998-1003. PubMed ID: 28610909
[TBL] [Abstract][Full Text] [Related]
47. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
48. Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models.
Mata M; Gerken C; Nguyen P; Krenciute G; Spencer DM; Gottschalk S
Cancer Discov; 2017 Nov; 7(11):1306-1319. PubMed ID: 28801306
[TBL] [Abstract][Full Text] [Related]
49. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.
Heczey A; Liu D; Tian G; Courtney AN; Wei J; Marinova E; Gao X; Guo L; Yvon E; Hicks J; Liu H; Dotti G; Metelitsa LS
Blood; 2014 Oct; 124(18):2824-33. PubMed ID: 25049283
[TBL] [Abstract][Full Text] [Related]
50. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.
Curran KJ; Seinstra BA; Nikhamin Y; Yeh R; Usachenko Y; van Leeuwen DG; Purdon T; Pegram HJ; Brentjens RJ
Mol Ther; 2015 Apr; 23(4):769-78. PubMed ID: 25582824
[TBL] [Abstract][Full Text] [Related]
51. Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy.
Zhang Y; Wang P; Wang T; Fang Y; Ding Y; Qian Q
J Transl Med; 2021 Feb; 19(1):82. PubMed ID: 33602263
[TBL] [Abstract][Full Text] [Related]
52. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.
Singh N; Frey NV; Engels B; Barrett DM; Shestova O; Ravikumar P; Cummins KD; Lee YG; Pajarillo R; Chun I; Shyu A; Highfill SL; Price A; Zhao L; Peng L; Granda B; Ramones M; Lu XM; Christian DA; Perazzelli J; Lacey SF; Roy NH; Burkhardt JK; Colomb F; Damra M; Abdel-Mohsen M; Liu T; Liu D; Standley DM; Young RM; Brogdon JL; Grupp SA; June CH; Maude SL; Gill S; Ruella M
Nat Med; 2021 May; 27(5):842-850. PubMed ID: 33888899
[TBL] [Abstract][Full Text] [Related]
53. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
54. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.
Moran AE; Kovacsovics-Bankowski M; Weinberg AD
Curr Opin Immunol; 2013 Apr; 25(2):230-7. PubMed ID: 23414607
[TBL] [Abstract][Full Text] [Related]
55. CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway.
Schattner EJ; Elkon KB; Yoo DH; Tumang J; Krammer PH; Crow MK; Friedman SM
J Exp Med; 1995 Nov; 182(5):1557-65. PubMed ID: 7595225
[TBL] [Abstract][Full Text] [Related]
56. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY
J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794
[TBL] [Abstract][Full Text] [Related]
57. T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy.
Yamamoto TN; Lee PH; Vodnala SK; Gurusamy D; Kishton RJ; Yu Z; Eidizadeh A; Eil R; Fioravanti J; Gattinoni L; Kochenderfer JN; Fry TJ; Aksoy BA; Hammerbacher JE; Cruz AC; Siegel RM; Restifo NP; Klebanoff CA
J Clin Invest; 2019 Feb; 129(4):1551-1565. PubMed ID: 30694219
[TBL] [Abstract][Full Text] [Related]
58. mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting.
Lohmueller JJ; Ham JD; Kvorjak M; Finn OJ
Oncoimmunology; 2017; 7(1):e1368604. PubMed ID: 29296519
[TBL] [Abstract][Full Text] [Related]
59. alpha-fetoprotein causes apoptosis in tumor cells via a pathway independent of CD95, TNFR1 and TNFR2 through activation of caspase-3-like proteases.
Dudich E; Semenkova L; Dudich I; Gorbatova E; Tochtamisheva N; Tatulov E; Nikolaeva M; Sukhikh G
Eur J Biochem; 1999 Dec; 266(3):750-61. PubMed ID: 10583368
[TBL] [Abstract][Full Text] [Related]
60. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity.
Frost P; Ng CP; Belldegrun A; Bonavida B
Cell Immunol; 1997 Aug; 180(1):70-83. PubMed ID: 9316641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
